A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

Phase 2

Completed

• Conditions: Metastatic Colorectal Cancer (mCRC)
• Interventions: Drug: -

• Registration Number: 2022-500177-13-00
• Lead Sponsor: Gilead Sciences Inc.

Brief Summary

The primary objectives of this study are:

Safety run-in cohort: to evaluate safety and tolerability, and the recommended Phase 2 dose (RP2D) and (randomized cohort) to evaluate the efficacy of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC).

Randomized Cohort: To evaluate the efficacy of magrolimab in combination with bevacizumab and FOLFIRI in mCRC as determined by progression-free survival (PFS) by investigator assessment

Detailed Description

Not available

Study Timeline

• Study First Posted: 2022-08-05
• Last Update Posted: 2024-04-02

Recruitment & Eligibility

• Status: Ended
• Sex: Not specified
• Target Recruitment: 46

Inclusion Criteria

Previously treated individuals with inoperable metastatic colorectal cancer (mCRC) who are ineligible for checkpoint inhibitor therapy (microsatellite instability (MSI)-H or mismatch repair deficient (dMMR) and are excluded).

Histologically or cytologically confirmed adenocarcinoma originating in the colon or rectum (excluding appendiceal and anal canal cancers) who have progressed on or after 1 prior systemic therapy in the setting where curative resection is not indicated. This therapy must have included chemotherapy based on 5-FU or capecitabine with oxaliplatin and either bevacizumab, or for patients with RAS wild-type and left-sided tumors, bevacizumab, cetuximab, or panitumumab.

Measurable disease (RECIST V1.1 criteria)

Individuals must have an eastern cooperative oncology group (ECOG) performance status of 0 or 1.

Life expectancy of at least 12 weeks.

Laboratory measurements, blood counts: adequate hemoglobin, neutrophil, and platelet counts

Adequate liver function

Adequate renal function

Note: Other protocol defined Inclusion criteria may apply

Exclusion Criteria

Prior anticancer therapy including chemotherapy, hormonal therapy, or investigational agents within 3 weeks or within at least 4 half-lives prior to magrolimab dosing (up to a maximum of 4 weeks), whichever is shorter.

Known dihydropyrimidine dehydrogenase deficiency.

History of abdominal fistulas, trachea-oesophageal fistulas, any other Grade 4 gastrointestinal perforations, nongastrointestinal fistulas, or intra-abdominal abscesses 6 months prior to screening.

Acute intestinal obstruction or subobstruction, history of inflammatory intestinal disease or extended resection of the small intestine. Presence of a colonic prosthesis.

Unhealed wound, active gastric or duodenal ulcer, or bone fracture.

Note: Other protocol defined Exclusion criteria may apply.

Uncontrolled arterial hypertension.

Thromboembolic event in the 6 months before inclusion (eg, transitory ischemic stroke, stroke, subarachnoid hemorrhage) except peripheral deep vein thrombosis treated with anticoagulants.

Active central nervous system (CNS) disease. Individuals with asymptomatic and stable, treated CNS lesions (radiation and/or surgery and/or other CNS-directed therapy who have not received corticosteroids for at least 4 weeks) are allowed.

Red blood cell (RBC) transfusion dependence, defined as requiring more than 2 units of packed RBC transfusions during the 4-week period prior to screening.

History of hemolytic anemia, autoimmune thrombocytopenia, or Evans syndrome in the last 3 months.

Significant disease or medical conditions, as assessed by the investigator and sponsor, that would substantially increase the risk-benefit ratio of participating in the study.

Known hypersensitivity to any of the study drugs, the metabolites, or formulation excipient.

Known inherited or acquired bleeding disorders.

Second malignancy, except treated basal cell or localized squamous skin carcinomas, or localized prostate cancer

Known v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E or MSI-H mutations or dMMR.

Uncontrolled pleural effusion.

Persistent Grade 2 or more gastrointestinal bleeding.

Individuals with prior irinotecan therapy.

Clinically significant coronary artery disease or myocardial infarction within 6 months prior to inclusion.

Peripheral neuropathy of more than Grade 2 (CTCAE Version 5.0).

Study & Design

• Study Type: Not specified
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
-	-	Participants receiving -

Primary Outcome Measures

Name	Time	Method
Safety Run-in Cohort: • Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [ Time Frame: First dose date up to 28 days ]		Safety Run-in Cohort: • Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [ Time Frame: First dose date up to 28 days ]
Safety Run-in Cohort: • Percentage of Participants Experiencing Adverse Events (AEs) According to the NCI-CTCAE Version 5.0 [ Time Frame: First dose date up to 3 years ] • Percentage of Participants Experiencing Laboratory Abnormalities According to NCI-CTCAE Version 5.0 [ Time Frame: First dose date up to 3 years ]		Safety Run-in Cohort: • Percentage of Participants Experiencing Adverse Events (AEs) According to the NCI-CTCAE Version 5.0 [ Time Frame: First dose date up to 3 years ] • Percentage of Participants Experiencing Laboratory Abnormalities According to NCI-CTCAE Version 5.0 [ Time Frame: First dose date up to 3 years ]
Randomized Cohort: • Progression-free Survival (PFS) as Determined by Investigator Assessment Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 [ Time Frame: Up to 3 years ] PFS is defined as the time from the date of randomization until the earliest date of documented disease progression, or death from any cause, whichever occurs first.		Randomized Cohort: • Progression-free Survival (PFS) as Determined by Investigator Assessment Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 [ Time Frame: Up to 3 years ] PFS is defined as the time from the date of randomization until the earliest date of documented disease progression, or death from any cause, whichever occurs first.

Trial Locations

Locations (18)

Hospital Universitario Hm San Chinarro; 🇪🇸 Madrid, Spain

Hospital Universitario 12 De Octubre; 🇪🇸 Madrid, Spain

Hospital Universitari Vall D Hebron; 🇪🇸 Barcelona, Spain

Hospital General Universitario Gregorio Maranon; 🇪🇸 Madrid, Spain

Catalan Institute Of Oncology; 🇪🇸 L'hospitalet De Llobregat, Spain

Klinikum Rechts Der Isar Der Technischen Universitat Munchen; 🇩🇪 Munich, Germany

Universitaetsklinikum Carl Gustav Carus An Der Technischen Universitaet Dresden AöR; 🇩🇪 Dresden, Germany

Hôpital De Libramont; 🇧🇪 Libramont-Chevigny, Belgium

Pôle Hospitalier Jolimont; 🇧🇪 La Louviere, Belgium

GCS IHFB Cognacq Jay Franco-British Hospital; 🇫🇷 Levallois Perret, France

Scroll for more (8 remaining)

Hospital Universitario Hm San Chinarro

🇪🇸Madrid, Spain

Antonio Cubillo Gracián

Site contact

+34917567984

acubillo@hmhospitales.com